Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22277837

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2012 Mar
First author
Ciuleanu T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2012 Mar;13(3):225-7. doi: 10.1016/S1470-2045(12)70001-3.
    note
    Source null
    related pmid
    22277836
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2012 Apr;13(4):e141-2; author reply e142. doi: 10.1016/S1470-2045(12)70113-4.
    note
    Source null
    related pmid
    22469123
    relationship
    Comment in

Authors and identifiers

  1. name
    Ciuleanu T
    type
    Author
  2. name
    Stelmakh L
    type
    Author
  3. name
    Cicenas S
    type
    Author
  4. name
    Miliauskas S
    type
    Author
  5. name
    Grigorescu AC
    type
    Author
  6. name
    Hillenbach C
    type
    Author
  7. name
    Johannsdottir HK
    type
    Author
  8. name
    Klughammer B
    type
    Author
  9. name
    Gonzalez EE
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ciuleanu T
    type
    Author
  2. name
    Stelmakh L
    type
    Author
  3. name
    Cicenas S
    type
    Author
  4. name
    Miliauskas S
    type
    Author
  5. name
    Grigorescu AC
    type
    Author
  6. name
    Hillenbach C
    type
    Author
  7. name
    Johannsdottir HK
    type
    Author
  8. name
    Klughammer B
    type
    Author
  9. name
    Gonzalez EE
    type
    Author
bibliography ids
  1. nci-bib-7f0af979305f481dc72d8aee
book metadata
content sha256
710726e50d9d9556534a125b7466c0264a3a67f92c327b52053c373ed2d19c19
document type
citation
dois
  1. 10.1016/S1470-2045(11)70385-0
electronic publication date
display
2012 Jan 24
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:22277837
immutable id
pubmed:22277837@710726e50d9d9556534a125b7466c0264a3a67f92c327b52053c373ed2d19c19
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
3
name
The Lancet. Oncology
nlm unique id
100957246
pages
300-8
volume
13
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2012 Mar;13(3):225-7. doi: 10.1016/S1470-2045(12)70001-3.
    note
    Source null
    related pmid
    22277836
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2012 Apr;13(4):e141-2; author reply e142. doi: 10.1016/S1470-2045(12)70113-4.
    note
    Source null
    related pmid
    22469123
    relationship
    Comment in
outcomes validated
false
pmid
22277837
provenance
batch id
b6284687e167e7da9556
provider
NCBI PubMed ESummary
record sha256
04429b6149065b55db9cad16db6b9bc88f6113b10b7de156a0374653474fa15e
response sha256
64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
retrieved at
2026-09-09T23:46:45.216259+00:00
publication date
display
2012 Mar
precision
month
year
2012
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22277837/
title
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Preserved source evidence · Not medical advice